Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
- 31 July 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (10) , 1344-1350
- https://doi.org/10.1016/j.ejca.2006.02.011
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancerJournal of Clinical Oncology, 2005
- End Points and United States Food and Drug Administration Approval of Oncology DrugsJournal of Clinical Oncology, 2003
- Prostate-specific antigen in prostate cancer: A case study in the development of a tumor marker to monitor recurrence and assess responseSeminars in Oncology, 2002
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end PointsJournal of the Royal Statistical Society Series C: Applied Statistics, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- The validation of surrogate endpoints in meta-analyses of randomized experimentsBiostatistics, 2000
- Criteria for the Validation of Surrogate Endpoints in Randomized ExperimentsPublished by JSTOR ,1998
- Meta-analysis for the evaluation of potential surrogate markersStatistics in Medicine, 1997
- Statistics notes: Absence of evidence is not evidence of absenceBMJ, 1995
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989